# A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine

> **NCT05652543** · PHASE2 · COMPLETED · sponsor: **Sinocelltech Ltd.** · enrollment: 518 (actual)

## Conditions studied

- COVID-19 Pandemic

## Interventions

- **BIOLOGICAL:** SCTV01E
- **BIOLOGICAL:** Placebo (normal saline)

## Key facts

- **NCT ID:** NCT05652543
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-05
- **Primary completion:** 2024-01-15
- **Final completion:** 2024-01-15
- **Target enrollment:** 518 (ACTUAL)
- **Last updated:** 2024-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05652543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05652543, "A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05652543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*